New Approaches to the Immunotherapy of Type 1 Diabetes Mellitus Using Interleukin-27

Fatemeh Zamani ^1,2, Shohreh Almasi ^1,2, Tohid Kazemi ^1,2, Rana Jahanban Esfahlan ³, Mohammad Reza Aliparasti ⁴ *

Cited by CrossRef: 5

1- Schenck S, Rosenbauer J, Niewerth M, Klotsche J, Minden K, Schwarz T, Foeldvari I, Horneff G, Weller-Heinemann F, Holl R, Thon A. Comorbidity of Type 1 Diabetes Mellitus in Patients with Juvenile Idiopathic Arthritis. The Journal of Pediatrics. 2018;192:196 [Crossref]

2- Luo J, Ning T, Li X, Jiang T, Tan S, Ma D. Targeting IL-12 family cytokines: A potential strategy for type 1 and type 2 diabetes mellitus. Biomedicine & Pharmacotherapy. 2024;170:115958 [Crossref]

3- Yahaya T, Salisu T. Genes predisposing to type 1 diabetes mellitus and pathophysiology: a narrative review. Med J Indones. 2020;29(1):100 [Crossref]

4- Madhumitha H, Mohan V, Babu S, Aravindhan V. TLR-induced secretion of novel cytokine IL-27 is defective in newly diagnosed type-2 diabetic subjects. Cytokine. 2018;104:65 [Crossref]

5- Yazdanpanah N, Yazdanpanah M, Wang Y, Forgetta V, Pollak M, Polychronakos C, Richards J, Manousaki D. Clinically Relevant Circulating Protein Biomarkers for Type 1 Diabetes: Evidence From a Two-Sample Mendelian Randomization Study. 2022;45(1):169 [Crossref]